{"id":"NCT02986854","sponsor":"GlaxoSmithKline","briefTitle":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","officialTitle":"A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-08","primaryCompletion":"2017-07-17","completion":"2017-12-07","firstPosted":"2016-12-08","resultsPosted":"2018-08-03","lastUpdate":"2019-11-25"},"enrollment":704,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)","otherNames":[]}],"arms":[{"label":"Menveo-Menveo Group","type":"EXPERIMENTAL"},{"label":"Menactra-Menveo Group","type":"EXPERIMENTAL"},{"label":"Naive Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose/aim of this study is to assess the safety and antibody response to vaccination with a booster dose of Menveo given 4-6 years after primary MenACWY vaccination and to assess the safety and antibody response to a single dose of Menveo given to vaccine-na√Øve subjects","primaryOutcome":{"measure":"Percentages of Subjects With Human Serum Bactericidal Antibody (hSBA) Seroresponse Against Neisseria Meningitidis Serogroups A, C, W and Y.","timeFrame":"At Day 29","effectByArm":[{"arm":"Menveo-Menveo Group","deltaMin":97.97,"sd":null},{"arm":"Menactra-Menveo Group","deltaMin":97.01,"sd":null},{"arm":"Pooled Group (Menveo-Menveo and Menactra-Menveo)","deltaMin":97.5,"sd":null},{"arm":"Naive Group","deltaMin":64.71,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG002 vs OG003","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":37,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["31495595"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&amp;parentIdentifier=205352&amp;attachmentIdentifier=4b9c0f0f-df12-453e-bed2-1e14b1b278a1&amp;fileName=gsk-205352-clinical-study-report-redact.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":301},"commonTop":["Injection site pain","Fatigue","Headache","Myalgia","Nausea"]}}